{'fraction_non_alphanumeric': 0.023178807947019868, 'fraction_numerical': 0.009933774834437087, 'mean_word_length': 5.754189944134078, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Daptomycin: first in a new class of antibiotics for complicated skin and soft‐tissue infections

With increasing antibiotic resistance reported worldwide, there is an urgent need for novel treatments for infections caused by Gram‐positive bacteria. Daptomycin is the first in a new class of antibiotic, the cyclic lipopeptides, with activity against a range of Gram‐positive pathogens. US approval of daptomycin for the treatment of complicated skin and soft‐tissue infections (cSSTIs) caused by Gram‐positive bacteria was gained in 2003, with European approval granted in January 2006. Most Gram‐positive clinical isolates tested have proved susceptible to daptomycin, including methicillin‐ and vancomycin‐resistant strains. Daptomycin has a novel mode of action, is rapidly bactericidal in vitro and has a low potential for the development of resistance. Two pivotal phase III studies, in a total of 1092 patients with cSSTIs, demonstrated non‐inferiority to currently used antibiotics and a comparable tolerability profile. The unique mode of action of daptomycin is described alongside studies demonstrating its potential in the treatment of cSSTIs and other infections caused by Gram‐positive bacteria.